<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: To describe the clinical outcome of three patients with <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease maintained on infliximab who were switched to adalimumab therapy </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Case note review </plain></SENT>
<SENT sid="2" pm="."><plain>Main outcome measure was recurrence of <z:hpo ids='HP_0000554'>uveitis</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: <z:hpo ids='HP_0000001'>All</z:hpo> patients remained free of recurrence with stable visual acuities </plain></SENT>
<SENT sid="4" pm="."><plain>CONCLUSIONS: Adalimumab appears to maintain disease remission in <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease </plain></SENT>
</text></document>